RxDoctor Payments DataLook up a doctor →

David Leff, DO

Gastroenterology · Mesa, AZNPI 1619956505

Payments from drug & device makers

$377,114in general payments, 2019–2025

Across 1,383 payments — averaging $272.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$160K
  • Sanofi$59K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$58K
  • Regeneron Healthcare Solutions, Inc.$34K
  • Gilead$32K
  • Aimmune Therapeutics, Inc.$7K
  • plus $28K from 47 others

What the payments were for

  • Consulting fees$2,2501%
  • Speaking & faculty fees$303,80781%
  • Travel & lodging$30,2338%
  • Food & beverage$38,36410%
  • Education$2,4601%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$377,114 in reported general payments places this provider in the 90th percentile of 355 gastroenterology providers in Arizona.

See all gastroenterology providers in Arizona

Medicare billing

Part B allowed, 2024
$120,111
Medicare patients
438
Services billed
833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab24$177,187
ZenpepLipase/Protease/Amylase33$123,277
XifaxanRifaximin23$85,093
LinzessLinaclotide89$78,726
TrulancePlecanatide22$16,889
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates118$7,661
ClenpiqSod Picosulf/Mag Ox/Citric Ac41$7,028
Dexlansoprazole DrDexlansoprazole18$4,828
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C33$4,798
Mesalamine25$4,476
Pantoprazole Sodium312$4,137
DexilantDexlansoprazole13$3,792
Lansoprazole51$2,300
Omeprazole82$1,742
Lactulose27$826

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$7,264$123,27733 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu$57,874$106,78078 claims
AbbVieLinzess$160,357$78,72689 claims
Ferring Pharmaceuticals Inc.Clenpiq$457$7,02841 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$158$3,79213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 355 gastroenterology providers in Arizona.

Other gastroenterology in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →